TI
RGLS

Trexquant Investment’s Regulus Therapeutics RGLS Stock Holding History

Trexquant Investment’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-414
Closed -$344K – 1060
2016
Q1 		$344K Sell
414
-524
-56% -$417K 0.04% 695
2015
Q4 		$982K Buy
+938
New +$940K 0.09% 401

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's RGLS Position: Q2 2016 in Review

Trexquant Investment sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 414 shares — an estimated $344K sold.

Trexquant Investment first reported a position in RGLS in Q4 2015 and held it in 2 quarters. The position peaked at $982K in Q4 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Trexquant Investment reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Trexquant Investment sold 414 Regulus Therapeutics shares in Q2 2016, an estimated $344K.
  • Trexquant Investment first reported a position in Regulus Therapeutics in Q4 2015 and held it in 2 quarters.
  • Trexquant Investment's Regulus Therapeutics position peaked at $982K in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Trexquant Investment's 13F filing for Q2 2016, filed 10 Aug 2016.